MedPath

Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging.

Not Applicable
Completed
Conditions
Migraine Without Aura
Registration Number
NCT04636359
Lead Sponsor
Beijing University of Chinese Medicine
Brief Summary

This study recruits 30 subjects into three groups, including two experimental groups and one control group. The two experimental groups receive acupuncture treatment for 4 weeks and two times functional magnetic resonance imaging scans as well as clinical symptom assessments. The control group receive one scan without any intervention. The aim of this study is to find the whether the effect of acupuncture treatment have diversity among migraineurs with different disease course.

Detailed Description

This study recruits 10 patients with long course (\> 5 years) without aura migraine, 10 patients with short course (\< 5 years) without aura migraine and 10 healthy volunteers who meet the inclusion and exclusion criteria. Among the study, two migraine patient groups receive acupuncture treatment for 4 weeks, the frequency is 30 minutes each time, three times a week. According to the national standard of the people's Republic of China (GB / T 12346-2006) acupoint name and location, the acupuncture treatment includes SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral) acupoints. Both migraine patients receive scan in functional magnetic resonance imaging (Siemens 3.0T superconducting magnetic resonance scanner, Germany) and symptom scale assessment before the first acupuncture stimulation and post the last acupuncture stimulation. Healthy volunteers receive only one scanning without intervention.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Fitting to the standard of migraine without aura in the international classification of headache disease (ICHD-2) issued by the international headache society in 2004.
  • Age from 18 to 55, male or female, with right-handedness.
  • Having no depression or other serious mental illness.
  • Having no psychoactive drugs taken in the past 3 months, or vasoactive drugs in the past 2 weeks.
  • Having no habit of taking analgesics from a long time.
Exclusion Criteria
  • Having the first headache attack of migraine after 55 years old.
  • Having a history of head injury, cluster headache, or other unclassified headaches.
  • Taking medicine to prevent migraine in recent 4 weeks.
  • Having the serious asymmetry or definite pathological changes in the anatomical structure of the head through the MRI scan.
  • Cannot hold on the times of the MRI scan.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Headache IntensityChange from Visual Analogue Scale at 1 months.

The headache intensity is measured by the value of Visual Analogue Scale which limits 1 to 10. The higher value of this scale represents the worse headache.

Headache DaysChange from the number of day at 1 months.

The days when headache attacked. The increased day represents the worse headache.

Headache FrequencyChange from the times of headache attack at 1 months.

The maximum times in one day during the headache attacked. The increased time represents the worse headache.

Dataset of functional magnetic resonance imaging on brainChanges from the dataset of subject's brain area at 1 months.

Dataset of functional magnetic resonance imaging on brain includes functional images, structural images and diffusion tensor images.

Secondary Outcome Measures
NameTimeMethod
Pittsburgh Sleep Quality IndexChange from the value of Pittsburgh Sleep Quality Index at 1 months.

One of the clinical measurement. The higher value represents the worse quality of sleep.

Medical Outcomes Study Short-Form 36 questionnaireChange from the value of Medical Outcomes Study Short-Form 36 questionnaire at 1 months.

One of the clinical measurement. The value range is 0 to 10, the higher value represents the better quality of life.

Trial Locations

Locations (1)

Dongzhimen Hospital

🇨🇳

Beijing, China

Dongzhimen Hospital
🇨🇳Beijing, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.